These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30930179)

  • 21. Effects of SKF-38393, a dopamine D1 receptor agonist on expression of amphetamine-induced behavioral sensitization and expression of immediate early gene arc in prefrontal cortex of rats.
    Moro H; Sato H; Ida I; Oshima A; Sakurai N; Shihara N; Horikawa Y; Mikuni M
    Pharmacol Biochem Behav; 2007 May; 87(1):56-64. PubMed ID: 17499349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
    Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393.
    Gleason SD; Witkin JM
    Behav Pharmacol; 2004 Feb; 15(1):85-9. PubMed ID: 15075630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
    Pollack AE; Yates TM
    Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 2. Intracerebral microinjection of dopamine agonists and antagonists.
    Okamura H; Murakami T; Yokoyama C; Nakamura T; Ibata Y
    J Pharmacol Exp Ther; 1997 Feb; 280(2):1031-7. PubMed ID: 9023320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.
    Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1995 Feb; 117(3):287-97. PubMed ID: 7770604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The PDE10A inhibitor, papaverine, differentially activates ERK in male and female rat striatal slices.
    Hsu YT; Liao G; Bi X; Oka T; Tamura S; Baudry M
    Neuropharmacology; 2011 Dec; 61(8):1275-81. PubMed ID: 21816164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Augmented sensitivity of D1-dopamine receptors in lateral but not medial striatum after 6-hydroxydopamine-induced lesions in the neonatal rat.
    Simson PE; Johnson KB; Jurevics HA; Criswell HE; Napier TC; Duncan GE; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1454-63. PubMed ID: 1361576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic interaction between serotonin-2 receptor and dopamine D1 receptor stimulation on striatal preprotachykinin mRNA expression in the 6-hydroxydopamine lesioned rat.
    Gresch PJ; Walker PD
    Brain Res Mol Brain Res; 1999 Jun; 70(1):125-34. PubMed ID: 10381550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG; Walters JR
    Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of full D1 dopamine receptor agonists on firing rates in the globus pallidus and substantia nigra pars compacta in vivo: tests for D1 receptor selectivity and comparisons to the partial agonist SKF 38393.
    Ruskin DN; Rawji SS; Walters JR
    J Pharmacol Exp Ther; 1998 Jul; 286(1):272-81. PubMed ID: 9655869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Motor stimulant effects of caffeine in 6-hydroxydopamine-lesioned rats are dependent on previous stimulation of dopamine receptors: a different role of D1 and D2 receptors.
    Fenu S; Morelli M
    Eur J Neurosci; 1998 May; 10(5):1878-84. PubMed ID: 9751157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
    Engber TM; Marin C; Susel Z; Chase TN
    Eur J Pharmacol; 1993 Jun; 236(3):385-93. PubMed ID: 8102970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. D1 dopamine receptor agonist (SKF-38393) induction of Fos immunoreactivity in progestin receptor-containing areas of female rat brain.
    Meredith JM; Auger AP; Blaustein JD
    J Neuroendocrinol; 1997 May; 9(5):385-94. PubMed ID: 9181492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434.
    Abrahams BS; Rutherford JD; Mallet PE; Beninger RJ
    Eur J Pharmacol; 1998 Feb; 343(2-3):111-8. PubMed ID: 9570457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic interactions of dopamine D1 and glutamate NMDA receptors in rat hippocampus and prefrontal cortex: involvement of ERK1/2 signaling.
    Sarantis K; Matsokis N; Angelatou F
    Neuroscience; 2009 Nov; 163(4):1135-45. PubMed ID: 19647050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parametric and pharmacological analyses of the enhanced grooming response elicited by the D1 dopamine receptor agonist SKF 38393 in the rat.
    Wachtel SR; Brooderson RJ; White FJ
    Psychopharmacology (Berl); 1992; 109(1-2):41-8. PubMed ID: 1365670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway.
    Yoshimura N; Kuno S; Chancellor MB; De Groat WC; Seki S
    Br J Pharmacol; 2003 Aug; 139(8):1425-32. PubMed ID: 12922929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons.
    Laprade N; Radja F; Reader TA; Soghomonian JJ
    J Neurosci; 1996 Jun; 16(11):3727-36. PubMed ID: 8642415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.